Beschreibung
Rosuvastatin and colchicine share BCRP transporter-mediated elimination; colchicine may weakly increase rosuvastatin exposure, and both carry myotoxic potential that could be additive.
Mechanismus
Rosuvastatin is a substrate of BCRP (ABCG2) and OATP1B1/1B3; colchicine inhibits BCRP to a minor degree, potentially raising rosuvastatin AUC slightly; additive myopathy risk from two agents with muscle toxicity profiles.
Klinische Bedeutung
The OATP/BCRP interaction is modest with colchicine; muscle toxicity cases have been reported for colchicine-statin combinations, although predominantly with CYP3A4-metabolised statins.
Maßnahmen
No routine dose adjustment is required; counsel patients to report muscle symptoms; measure CK if myopathy is suspected.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.